ANIX · Anixa Biosciences Inc · Insider Trading

$3.18 +0.15 (+4.79%) At close · Nov 6

Market Cap

$110.38M

34.76M

Volume · Nov 6 121.65K Avg daily vol (3M) 277.39K

Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.

Query insider transactions through the insider trading API or MCP →

Insider Sentiment Score Cluster buy

Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.

Net buyers

Net shares bought

0.30%

Net buy value

+$291,586

Date	Insider	Role	Type	Security	Shares	Price	Value	After
2026-10-30	KUMAR AMIT	Director, Chief Executive Officer	Buy↑	Common Stock	5,000	$3.17	$15,850	685,000
2026-10-23	Titterton Lewis H jr	Director	Buy↑	Common Stock	8,000	$2.98	$23,840	1,054,003
2026-10-22	KUMAR AMIT	Director, Chief Executive Officer	Buy↑	Common Stock	8,000	$2.72	$21,760	680,000
2026-09-30	Catelani Michael	President, COO & CFO	Buy↑	Common Stock	5,500	$2.84	$15,620	50,000
2026-09-24	KUMAR AMIT	Director, Chief Executive Officer	Buy↑	Common Stock	7,000	$2.78	$19,460	672,000
2026-09-24	Baskies Arnold M	Director	Buy↑	Common Stock	5,000	$2.76	$13,800	140,572
2026-09-23	Titterton Lewis H jr	Director	Buy↑	Common Stock	49,036	$2.69	$131,907	1,046,003
2026-09-10	Titterton Lewis H jr	Director	Buy↑	Common Stock	10,000	$2.73	$27,300	996,967
2026-09-10	KUMAR AMIT	Director, Chief Executive Officer	Buy↑	Common Stock	3,000	$2.75	$8,250	665,000
2026-09-10	KUMAR AMIT	Director, Chief Executive Officer	Buy↑	Common Stock	5,000	$2.76	$13,800	662,000
2026-07-31	KUMAR AMIT	Director, Chief Executive Officer	Buy↑	Common Stock	5,000	$3.47	$17,350	657,000
2026-07-27	Baskies Arnold M	Director	Convert↑	Common Stock	6,000	$3.13	$18,780	141,000
2026-07-27	KUMAR AMIT	Director, Chief Executive Officer	Buy↑	Common Stock	5,000	$3.44	$17,200	652,000
2026-07-27	KUMAR AMIT	Director, Chief Executive Officer	Buy↑	Common Stock	3,188	$3.37	$10,744	647,000
2026-07-27	Baskies Arnold M	Director	Tax↓ Filing footnotes — Common Stock (Direct) The reporting person exercised the stock options at this time due to their expiration on August 23, 2026. The disposal of shares reported herein represents shares withheld by Anixa Biosciences, Inc. (the "registrant") to cover the exercise price of the stock options.	Common Stock	5,428	$3.46	$18,781	135,572
2026-07-27	Baskies Arnold M	Director	Convert↓ Filing footnotes — Employee Stock Option (Right to Buy) (Direct) Right-To-Buy, pursuant to a stock option grant dated August 23, 2013.	Employee Stock Option (Right to Buy)	6,000	—	—	0
2026-07-24	KUMAR AMIT	Director, Chief Executive Officer	Buy↑	Common Stock	3,000	$3.73	$11,190	643,812
2026-07-20	Titterton Lewis H jr	Director	Buy↑	Common Stock	12,000	$3.47	$41,640	986,967
2026-07-20	KUMAR AMIT	Director, Chief Executive Officer	Buy↑	Common Stock	5,000	$3.46	$17,300	640,812
2026-07-15	Titterton Lewis H jr	Director	Buy↑	Common Stock	2,797	$3.28	$9,174	974,967
2026-07-10	KUMAR AMIT	Director, Chief Executive Officer	Buy↑	Common Stock	5,000	$3.04	$15,200	635,812
2026-06-16	Titterton Lewis H jr	Director	Buy↑	Common Stock	2,836	$2.64	$7,487	972,170
2026-06-12	KUMAR AMIT	Director, Chief Executive Officer	Buy↑	Common Stock	21,000	$2.50	$52,500	630,812
2026-01-28	Baskies Arnold M	Director	Buy↑	Common Stock	10,000	$3.04	$30,400	135,000
2026-01-05	Baskies Arnold M	Director	Award↑ Filing footnotes — Employee Stock Option (Direct) Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan. The options vest and become exercisable in twelve (12) equal monthly installments beginning January 31, 2026.	Employee Stock Option	25,000	—	—	25,000
2026-01-05	Gottschalk Emily	Director	Award↑ Filing footnotes — Employee Stock Option (Direct) Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan. The options vest and become exercisable in twelve (12) equal monthly installments beginning January 31, 2026.	Employee Stock Option	25,000	—	—	25,000
2026-01-05	Titterton Lewis H jr	Director	Award↑ Filing footnotes — Employee Stock Option (Direct) Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan. The options vest and become exercisable in twelve (12) equal monthly installments beginning January 31, 2026.	Employee Stock Option	25,000	—	—	25,000
2026-01-05	Catelani Michael	President, COO & CFO	Award↑ Filing footnotes — Employee Stock Option (Direct) Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan. The options vest and become exercisable in thirty-six (36) equal monthly installments beginning January 31, 2026.	Employee Stock Option	175,000	—	—	175,000
2026-01-05	KUMAR AMIT	Director, Chief Executive Officer	Award↑ Filing footnotes — Employee Stock Option (Direct) Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan. The options vest and become exercisable in thirty-six (36) equal monthly installments beginning January 31, 2026.	Employee Stock Option	350,000	—	—	350,000
2025-12-15	Titterton Lewis H jr	Director	Convert↓ Filing footnotes — Employee Stock Option (Direct) Right-To-Buy, pursuant to a stock option grant dated February 18, 2016.	Employee Stock Option	16,000	—	—	0
2025-12-15	Titterton Lewis H jr	Director	Convert↑	Common Stock	16,000	$2.92	$46,720	969,334
2025-10-30	KUMAR AMIT	Director, Chief Executive Officer	Convert↑	Common Stock	200,000	$2.92	$584,000	779,925
2025-10-30	KUMAR AMIT	Director, Chief Executive Officer	Tax↓ Filing footnotes — Common Stock (Direct) The reporting person exercised the stock options at this time due to their upcoming expiration on February 18, 2026. The disposal of shares reported herein represents shares withheld by Anixa Biosciences, Inc. (the "registrant") to (i) cover the exercise price of the stock options and (ii) satisfy tax withholding obligations in connection with the exercise of the stock options. Dr. Kumar did not sell any shares in connection with the exercise of the options.	Common Stock	169,439	$4.06	$687,922	610,486
2025-10-30	KUMAR AMIT	Director, Chief Executive Officer	Convert↓ Filing footnotes — Employee Stock Option (Right to Buy) (Direct) Right-To-Buy, pursuant to a stock option grant dated February 18, 2016. The option vested in 36 consecutive monthly installments beginning on March 31, 2016.	Employee Stock Option (Right to Buy)	200,000	—	—	0
2025-07-31	Titterton Lewis H jr	Director	Buy↑	Common Stock	10,000	$3.08	$30,800	953,334
2025-07-30	KUMAR AMIT	Director, Chief Executive Officer	Buy↑	Common Stock	5,000	$3.16	$15,800	579,925
2025-07-18	Baskies Arnold M	Director	Buy↑	Common Stock	5,000	$3.39	$16,950	125,000
2025-07-11	KUMAR AMIT	Director, Chief Executive Officer	Buy↑	Common Stock	5,000	$3.15	$15,750	574,925
2025-07-11	Titterton Lewis H jr	Director	Buy↑	Common Stock	10,000	$3.14	$31,400	943,334
2025-06-04	KUMAR AMIT	Director, Chief Executive Officer	Buy↑	Common Stock	10,000	$2.85	$28,500	569,925
2025-01-28	Baskies Arnold M	Director	Buy↑	Common Stock	5,000	$2.82	$14,100	120,000
2025-01-24	Titterton Lewis H jr	Director	Buy↑	Common Stock	1,000	$3.00	$3,000	933,334
2025-01-23	Titterton Lewis H jr	Director	Buy↑	Common Stock	2,000	$2.91	$5,820	932,334
2025-01-22	Titterton Lewis H jr	Director	Buy↑	Common Stock	2,000	$3.01	$6,020	930,334
2025-01-21	Titterton Lewis H jr	Director	Buy↑	Common Stock	6,000	$2.59	$15,540	928,334
2025-01-17	Titterton Lewis H jr	Director	Buy↑	Common Stock	10,000	$2.57	$25,700	922,334
2025-01-15	KUMAR AMIT	Director, Chief Executive Officer	Buy↑	Common Stock	43,000	$2.23	$95,890	559,925
2025-01-15	Catelani Michael	President, COO & CFO	Buy↑	Common Stock	9,289	$2.15	$19,971	44,500
2025-01-02	Titterton Lewis H jr	Director	Award↑ Filing footnotes — Employee Stock Option (Direct) Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan. The options vest and become exercisable in twelve (12) equal monthly installments beginning January 31, 2025.	Employee Stock Option	25,000	—	—	25,000
2025-01-02	KUMAR AMIT	Director, Chief Executive Officer	Award↑ Filing footnotes — Employee Stock Option (Direct) Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan. The options vest and become exercisable in thirty-six (36) equal monthly installments beginning January 31, 2025.	Employee Stock Option	700,000	—	—	700,000

Legend Buy — open-market purchase Sell — open-market sale ↑ Shares acquired ↓ Shares disposed (gift, conversion, tax…)

Showing 1–50 of 172 transactions

Key facts CIK 715446 CUSIP 03528H109 13F (30d) 25 filings 25 filers Visit website Investor relations